4-APB

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| image = 4APB structure.png

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Serotonin–norepinephrine–dopamine releasing agent

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 286834-83-1

| CAS_supplemental =

| PubChem = 10130546

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 8306061

| UNII = BXL47QK09N

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = 4-(2-Aminopropyl)benzofuran; 4-APB

| IUPAC_name = 1-(1-benzofuran-4-yl)propan-2-amine

| C=11 | H=13 | N=1 | O=1

| SMILES = CC(CC1=C2C=COC2=CC=C1)N

| StdInChI = 1S/C11H13NO/c1-8(12)7-9-3-2-4-11-10(9)5-6-13-11/h2-6,8H,7,12H2,1H3

| StdInChIKey = XROLBZOMVNMIFN-UHFFFAOYSA-N

}}

4-(2-Aminopropyl)benzofuran (4-APB) is a monoamine releasing agent and novel designer drug of the benzofuran family.{{cite web | title=Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA | website=Europol | date=23 October 2018 | url=https://www.europol.europa.eu/publication-events/publications/emcdda-europol-2011-annual-report-implementation-of-council-decision-2005/387/jha | access-date=27 February 2025}}{{cite journal | vauthors = Stanczuk A, Morris N, Gardner EA, Kavanagh P | title = Identification of (2-aminopropyl)benzofuran (APB) phenyl ring positional isomers in internet purchased products | journal = Drug Test Anal | volume = 5 | issue = 4 | pages = 270–276 | date = April 2013 | pmid = 23349125 | doi = 10.1002/dta.1451 | url = }}{{cite journal | vauthors = Casale JF, Hays PA | title = The characterization of 6-(2-aminopropyl) benzofuran and differentiation from its 4-, 5-, and 7-positional analogues. | journal = Microgram Journal | date = 2012 | volume = 9 | issue = 2 | pages = 61-74 | url = https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_61-74.pdf }}{{cite journal | vauthors = Simmler LD, Liechti ME | title = Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances | journal = Handb Exp Pharmacol | series = Handbook of Experimental Pharmacology | volume = 252 | issue = | pages = 143–164 | date = 2018 | pmid = 29633178 | doi = 10.1007/164_2018_113 | isbn = 978-3-030-10560-0 | url = }}{{cite journal | vauthors = Rickli A, Kopf S, Hoener MC, Liechti ME | title = Pharmacological profile of novel psychoactive benzofurans | journal = Br J Pharmacol | volume = 172 | issue = 13 | pages = 3412–3425 | date = July 2015 | pmid = 25765500 | pmc = 4500375 | doi = 10.1111/bph.13128 | url = }} It acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). The drug was first detected, in Europe, by 2011.